Reported 24 days ago
Investors who missed out on Viking Therapeutics (VKTX), which surged over 300% due to positive clinical results, are looking at Terns Pharmaceuticals (TERN) as a promising alternative in the weight loss biotech sector. Terns has recently reported favorable phase 1 results for its anti-obesity drug TERN-601 and plans to advance to phase 2 by 2025. While investing in Terns presents higher clinical risk, it also carries significant potential upside, particularly if its drug showcases superior tolerability and efficacy compared to existing market options. Given its solid funding, Terns could become a valuable opportunity for risk-tolerant investors.
Source: YAHOO